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Chir99021 and Valproic acid reduce the
proliferative advantage of Apc mutant cells
Alistair J. Langlands1,2, Thomas D. Carroll1, Yu Chen1 and Inke Näthke 1
Abstract
More than 90% of colorectal cancers carry mutations in Apc that drive tumourigenesis. A 'just-right' signalling model
proposes that Apc mutations stimulate optimal, but not excessive Wnt signalling, resulting in a growth advantage of
Apc mutant over wild-type cells. Reversal of this growth advantage constitutes a potential therapeutic approach. We
utilised intestinal organoids to compare the growth of Apc mutant and wild-type cells. Organoids derived from ApcMin/
+ mice recapitulate stages of intestinal polyposis in culture. They eventually form spherical cysts that reﬂect the
competitive growth advantage of cells that have undergone loss of heterozygosity (LOH). We discovered that this
emergence of cysts was inhibited by Chiron99021 and Valproic acid, which potentiates Wnt signalling. Chiron99021
and Valproic acid restrict the growth advantage of Apc mutant cells while stimulating that of wild-type cells,
suggesting that excessive Wnt signalling reduces the relative ﬁtness of Apc mutant cells. As a proof of concept, we
demonstrated that Chiron99021-treated Apc mutant organoids were rendered susceptible to TSA-induced apoptosis,
while wild-type cells were protected.
Introduction
The Wnt signalling pathway is an important regulator
of intestinal crypt homoeostasis. It is required for main-
tenance of intestinal stem cells1,2, and regulates pro-
liferation, migration and differentiation3 in intestinal
crypts. Activating the Wnt pathway is strongly associated
with colorectal cancer. Indeed, >90% of all colorectal
cancers carry mutations in Adenomatous polyposis coli
(Apc)4, which increases Wnt signalling.
Mice and patients heterozygous for mutations in Apc
invariably develop intestinal polyps. Where in the
intestinal-tract-speciﬁc Apc mutations produce lesions
most commonly is likely related to the endogenous Wnt
signal that exists locally plus the increased signal gener-
ated by the mutation5. Endogenous Wnt signalling
changes along the proximal distal axis of the intestinal
tract6,7. Together with predicted differences in Wnt sig-
nalling changes produced by different Apc mutations,
these ideas have led to the 'just-right' hypothesis8,9. It
postulates that speciﬁc Apc mutations are selected to
provide optimal Wnt signalling and to provide the
greatest proliferative advantage over surrounding wild-
type tissue.
Inhibitors of Wnt signalling are being considered as
potential anti-cancer treatments. They aim to inhibit the
advantage conferred by optimal Wnt signalling on Apc
mutant cells10. For such therapies to be successful, it is
crucial to understand how modifying Wnt signalling
affects the relative growth advantage of Apc mutant cells
over wild-type cells. Other signalling pathways, particu-
larly Notch and BMP, also contribute to responses of cells
to Wnt, complicating the situation and making it difﬁcult
to study how single factors affect relative growth, parti-
cularly in whole animals (reviewed in refs.11,12).
Intestinal organoids provide a useful model system to
investigate the relative growth advantage of different cells
in the context of the intestinal epithelium13. They
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constitute a powerful tool for measuring the effect
of potential cancer therapies, without the ethical
and cost implications of animal experimentation13. The
ApcMin/+ mouse has been used extensively to study early
stages of cancer14,15. Organoids derived from ApcMin/+
mice recapitulate polyp development in vivo; they initially
maintain normal crypt–villus architecture, but eventually
grow as spherical cysts reﬂecting the selective growth
advantage of cells that have undergone LOH16. Cells in
these spherical ApcMin/Min organoids have prominent
nuclear β-catenin, consistent with elevated Wnt
signalling.
Here, we demonstrate that treatment with the small
molecule inhibitors, Chiron99021 (C) and Valproic acid
(V), reduces the growth advantage of Apc mutant cells at
concentrations that activate Wnt and Notch signalling17.
We found that CV treatment prevented the transforma-
tion of ApcMin/+ to ApcMin/Min organoids. The latter grew
relatively more slowly in CV, but there was no increase in
apoptosis. Sensitising ApcMin/Min organoids by potentiat-
ing Wnt signalling rendered them more susceptible to
TSA-induced death, while it protected wild-type orga-
noids. These results provide a proof-of-concept for the
idea that excessive Wnt stimulation can reduce the ﬁtness
of Apc mutant cells and render them more susceptible to
death.
Results
Characterisation of ApcMin/+ organoids
We ﬁrst established that organoids were appropriate
surrogates for tissue in situ by examining whether they
recapitulate polyp development. Organoids isolated from
ApcMin/+ mice were initially indistinguishable from wild-
type organoids, but after a few passages they grew as
spherical cysts that only contained cells that had under-
gone LOH (Fig. 1; Figure S1A-C) as reported previously16.
The wild-type and mutant alleles of Apc were consistently
detected in ApcMin/+, but only the mutant form was
detected in ApcMin/Min cysts (Figure S1A). Similar to
Apcﬂ/ﬂ cysts18, epithelial polarity was maintained in
ApcMin/Min cysts, as revealed by the presence of apical
ZO1, lateral E-cad and basal β4 integrin (Fig. 1a). How-
ever, the distribution of the different cell types normally
found in the intestinal epithelium was altered. In both
wild-type and ApcMin/+ organoids, mitotic (phospho-his-
tone3 positive, PH3+), and proliferative (Ki67+) cells
localised exclusively to crypts and Paneth cells were
restricted to crypt bases (Fig. 1a). In ApcMin/Min cysts,
most cells were proliferative (Ki67+), and mitotic and
Paneth cells were distributed throughout the cyst (Fig. 1a).
The maintenance of epithelial polarity and loss of tissue
organisation was similar to that in polyps in situ in
ApcMin/+ mice (Fig. 1b), which represent tissue formed by
cells that have undergone LOH in Apc. These data
conﬁrm that cells which have undergone LOH in orga-
noids and tissue form similar structures.
Mutations in Apc lead to elevated Wnt signalling in
polyps in ApcMin/+ mice. The accumulation of nuclear β-
catenin in ApcMin/Min suggests that the same is true in
organoids16. Increased Wnt signalling in ApcMin/Min cysts
was conﬁrmed by an increase in the amount of β-catenin
protein (Figure S1B, C) and elevated expression of
mRNA-encoding Axin2, CycD and cMyc (Figure S1D).
None of the examined genes were altered in ApcMin/+
organoids relative to wildtype while they exhibited normal
organoid morphology (Figure S1D). In tissue homozygous
mutant for Apc, the number of differentiated intestinal
cells is reduced19. Consistently, expression of differ-
entiated cell markers was reduced in ApcMin/Min, but not
ApcMin/+ organoids (Figure S1D, E), conﬁrming that
mutation of both Apc alleles is required to induce
tumourigenic changes.
Other reported changes in Apc mutant tissue include
elevated expression of EMT markers20,21. Consistently, we
found that in ApcMin/Min cysts, mRNA for both N-cad and
Vim was also increased (Figure S1F). However, E-cad
remained more highly expressed than N-cad and the ratio
of E-cad:N-cad in ApcMin/Min was similar to that in wild-
type organoids. In comparison, in mouse ﬁbroblasts,
representative of mesenchymal cells, the E-cad:N-cad
ratio was much lower (Figure S1G). Consistent with their
epithelial characteristics, ApcMin/Min cysts maintained
normal levels of E-cad protein (Figure S1H, I).
Together, these results conﬁrmed that ApcMin/Min cysts
are phenotypically similar to polyps that appear in
ApcMin/+ intestinal tissue and reﬂect structures formed
by cells that had undergone LOH, validating them as a
suitable model for early tumourigenesis.
Chiron99021 and Valproic acid prevent tumourigenic
transformation of ApcMin/+ organoids
Chiron99021 and Valproic acid are commonly included
in early passages for organoid culture because they
improve the efﬁciency of organoid formation. They
increase Wnt and Notch signalling resulting in the pre-
sence of more Lgr5+ stem cells17. Surprisingly, these
reagents prevented the transformation of ApcMin/+ orga-
noids. ApcMin/+ organoids robustly formed spherical cysts
after repeated passage in normal (ENR) media. However,
when grown in normal media (ENR) supplemented with
Chiron 99021 and Valproic acid (ENR-CV), they main-
tained normal morphology (Fig. 2a, b). Genotyping
revealed that the wild-type allele persisted in ENR-CV but
was lost in ENR (Fig. 2c). We wanted to determine
whether a reduction in the rate of LOH or a shift in the
relative growth advantage of ApcMin/+ and ApcMin/Min
cells was responsible for these observations. The number
and size of polyps in ApcMin/+ mice increase with age
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reﬂecting the increasing number of LOH events in the
tissue22. If cyst formation reﬂects the relative outgrowth
of ApcMin/Min present at the time of tissue isolation, cysts
should appear more rapidly in organoid cultures estab-
lished from older mice. Indeed, organoids isolated from
~60-day-old ApcMin/+ mice transformed into cysts less
frequently than those isolated from ~90-day-old ApcMin/+
mice (Figure S2). These observations are consistent with
the idea that ApcMin/Min cysts in culture emerged from
ApcMin/Min cells that had undergone LOH in the animal
before tissue isolation. This is also consistent with the
observation that ApcMin/+ organoids are genetically stable
in culture23 and suggests that Chiron 99021 and Valproic
acid reduces the growth advantage of ApcMin/Min cells.
To test this idea further, we mixed ApcMin/+ and
ApcMin/Min organoids, and compared the growth in ENR
Fig. 1 ApcMin/Min organoids maintain epithelial polarity but lose tissue organisation. a Apical-basal polarity is maintained in ApcMin/+ organoids
as revealed in single optical sections of wild-type (upper panel), ApcMin/+ (middle panel) and ApcMin/Min (lower panel) organoids stained with Hoechst
(blue) and Phalloidin (magenta) to visualise nuclei and actin; ZO1 (green, left panel), E-cadherin (green, middle panel) and β4 integrin (green, right
panel) mark apical, lateral and basal membranes, respectively. Crypt–villus organisation is lost in ApcMin/Min organoids, as revealed in maximum
intensity projections (far right panels) of organoids stained to reveal actin (Phalloidin, magenta); Lysozyme (Paneth cells, green), PH3 (mitotic cells,
cyan), left panel; and Ki67 (proliferative cells, green), right panel. ApcMin/+ organoids were imaged in the ﬁrst three passages after isolation, ApcMin/Min
were imaged after at least ﬁve passages. Scale bars = 50 µm. b Cryo-sectioned intestinal tissue from wild-type mice (upper panel) and from polyps in
ApcMin/+ mice (lower panel) stained with Hoechst (blue) and Phalloidin (magenta). Localisation of polarity markers (green: ZO1, left panel; E-cad,
middle panel; and β4 integrin, right panel) reveals that epithelial polarity is maintained in polyps. Vibratome-sectioned intestinal tissue stained to
detect Lysozyme (white) reveals Paneth cells at the crypt base in wild-type tissue, but distributed throughout polyps. Cryo-sectioned intestinal tissue
stained against Ki67 (green) reveals that proliferative epithelial cells are restricted to crypts in wild-type tissue, while almost all cells in a polyp are
proliferative. Scale bars = 100 µm
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and ENR-CV (Fig. 2d). After one passage in ENR, the wild-
type allele was barely detectable suggesting that fewer
heterozygous cells were present. However, the wild-type
allele became more abundant again when the same orga-
noids were transferred to and then passaged in ENR-CV,
but not when they continued to grow in ENR (Fig. 2e).
These data conﬁrmed that ENR-CV altered the relative
growth advantage of wild-type and ApcMin/Min organoids.
The altered growth advantage in ENR-CV may be
caused by increased growth of wild-type organoids,
reduced growth of ApcMin/Min cysts or both. To determine
how ENR-CV alters growth advantage, we examined
growth of wild-type and ApcMin/Min organoids in ENR-
CV, ENR-C, ENR-V and ENR. ApcMin/Min cysts grew
signiﬁcantly more slowly in ENR-CV, while growth of
wild-type organoids did not signiﬁcantly change
(Fig. 3a–c). The reduced growth of ApcMin/Min cysts may
be caused by reduced proliferation or an increase in
apoptosis. Viability assays revealed that ENR-CV
increased the formation and growth of wild-type orga-
noids but slightly decreased the growth of ApcMin/Min
cysts (Fig. 3d–f). There was no increase in Caspase-3
activity in wild-type or ApcMin/Min organoids grown in
ENR-CV, suggesting that apoptosis was not affected
(Fig. 3g). These data indicate that changes in proliferation
are most likely responsible for the differential growth
Fig. 2 Chiron99021 and Valproic acid inhibit formation of ApcMin/Min cysts. a Images of organoids derived from ApcMin/+ after one (left) and two
(right) passages in ENR or ENR-CV. b Proportion (%) of total organoids exhibiting cyst morphology at the end of each passage in ENR and ENR-CV. c
Genotyping of organoids at the end of each passage shows that ApcMin/+ organoids grown in ENR-CV maintain the wild-type Apc allele while only
the mutant allele is detectable in ENR. d Equal numbers of wild-type and ApcMin/Min organoids were mixed, and the percentage of organoids growing
as cysts was determined after successive passages. e Genotyping of the mixed populations of wild-type and ApcMin/Min organoids shown in (d)
conﬁrms the disappearance of the wild-type allele in ENR and its re-emergence in ENR-CV corresponding to the relative abundance of cysts in each
case
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advantages of organoids in ENR-CV. To determine whe-
ther these changes in growth are recapitulated con-
sistently in human cells, we compared the effect of
Chiron99021 and Valproic acid on HAB92 colorectal
cancer cells (a derivative of HCT116 cells, which are
homozygous for wild-type β-catenin)24 transfected with
siRNA-targeting Apc or a control (scrambled) siRNA.
Consistent with our hypothesis, cells lacking APC were
less viable than cells transfected with control siRNA when
grown in Chiron99021 or Chiron99021 plus Valproic acid
(Fig. 3h).
The growth advantage of ApcMin/Min cells reﬂects 'just-right'
Wnt signalling
Gene expression analysis of organoids has shown that
ENR-CV stimulates Wnt signalling17. Together with the
'just-right' Wnt signalling hypothesis7, this data prompted
us to test whether reduced growth of ApcMin/Min
Fig. 3 (See legend on next page.)
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organoids in ENR-CV is related to activation of Wnt
signalling beyond an optimal level. TOP/FOP assays
performed in HEK293 cells conﬁrmed that treatment with
Chiron99021 alone, or Chiron99021 plus Valproic acid
potently increased Wnt signalling, more so than treat-
ment with Wnt3A-conditioned media (Figure S3A). The
amount of β-catenin protein was increased when HAB92
cells were treated with Chiron99021 and/or Valproic acid
(Figure S3B, D), including in cells depleted of APC (Fig-
ure S3D). Exogenous Wnt3A increased β-catenin protein
levels in control siRNA-transfected HAB92 cells, although
it did not increase β-catenin levels in cells depleted of
APC (Figure S3C, E).
We then examined whether directly stimulating Wnt
could alter the growth of organoids. Exposure to increasing
amounts of Wnt3A-conditioned media slowed the growth
of ApcMin/Min cysts, but did not signiﬁcantly change the
growth of wild-type organoids (Fig. 4a, b). Similarly,
treatment of HAB92 cells with Wnt3A-conditioned media
increased the viability of cells transfected with control
siRNA more than of those transfected with siApc (Fig. 4c).
Differences in relative growth between the organoid and
cell culture models may be explained by the incomplete
knock-down of APC in the cell culture model (Figure S3D).
Neverthless, these data support the idea that Wnt signal-
ling above an optimal level could at least be partially
responsible for the observed changes in organoid growth
advantage. Treatment of organoids with Chiron99021 and
Valproic acid may put Wnt signalling above the optimal
level for ApcMin/Min, while putting Wnt signalling in wild-
type or ApcMin/+ organoids closer to the optimal level (see
schematic in Fig. 4d).
There did not appear to be a direct correlation between
β-catenin protein level and cell viability measured in
HAB92 cells (Fig. 4c; Figure S3E), suggesting that there is
not a simple relationship between Wnt signal received,
β-catenin protein level and cell growth. To understand
whether this relationship could be explained by different
transcriptional outputs, we compared the transcription of
a panel of Wnt target genes in wild-type, ApcMin/+ and
ApcMin/Min organoids. We found that the expression of all
the genes we analysed was indistinguishable between wild-
type and ApcMin/+ organoids, but many were signiﬁcantly
upregulated or downregulated in ApcMin/Min cysts (Fig-
ure S4). We then compared these genes in wild-type and
ApcMin/+ organoids treated with Chiron99021 and/or
Valproic acid. This analysis revealed a range of responses
for different Wnt targets (Figure S4), suggesting a highly
complex relationship between transcriptional responses,
Wnt signalling and organoid growth that cannot be
explained simply by the activity and function of Wnt target
genes. In addition, many Wnt target genes respond to
Valproic acid on its own (Figure S4). Thus identifying the
speciﬁc Wnt targets responsible for the differential growth
advantages of wild-type and Apc mutant cells under dif-
ferent growth conditions, will require a much more
extensive and detailed analysis of the temporal dynamics
and quantitative changes in transcriptional proﬁles.
(see ﬁgure on previous page)
Fig. 3 Growth of ApcMin/Min organoids is slowed in ENR-CV. a, b Images of wild-type (a) and ApcMin/Min (b) organoids after 72 h treated as
indicated with either Chir99021 (‘ENR-C’) and/or Valproic acid (‘ENR-CV’ or ‘ENR-V’). c Quantifying organoid growth over 72 h revealed decreased
growth of ApcMin/Min organoids in ENR-CV only (p = 0.02), while growth of wild-type organoids was unaffected (average of three experiments ± SD,
statistical signiﬁcance for each condition compared to ENR by t test). d Schematic representation of experimental design to measure organoid
recovery and growth after passaging to single cells using viability assays. Single cells from wild-type or ApcMin/Min organoids were grown in ENR ± CV
containing Y27632 for 3 days (at this point they only form spheroids representing early growth from single cells), and for a further 3 days in ENR ± CV
without Y27632 to form organoids or cysts. Viability was determined by measuring relative luminescence intensity using CellTiterGLO, and measured
for parallel cultures after 3 days and 6 days. Wells containing wildtype and ApcMin/Min were set up in parallel. Three technical replicates were
performed in each case and the results shown are from three (ENR) or four (ENR-CV) independent experiments. e Relative luminescence intensity of
wild-type and ApcMin/Min spheroids (white bars) and organoids/cysts (grey bars) were measured as described in (d). Initial growth in ENR-CV
signiﬁcantly increased the viability of wild-type spheroids (p < 0.0001) and organoids (p < 0.0001), but did not signiﬁcantly change the viability of
ApcMin/Min spheroids (p = 0.6172) and reduced the viability of ApcMin/Min cysts (p = 0.0207). These data show that wild-type spheroids form and grow to
organoids much more readily in ENR-CV than in ENR, while ApcMin/Min spheroid formation and growth to cysts is slightly reduced under these
conditions. Bar graph shows average values ± SEM. Kolmogorov–Smirnov tests to compare distribution of values were performed to assess statistical
signiﬁcance. f Relative growth of wildtype and ApcMin/Min from spheroids to organoids. Relative organoid growth was calculated by dividing the
average luminescence intensity of organoids (grey bars in e) by the average luminescence intensity of the preceding spheroid stage for each of three
independent experiments (values represented by white bars in e). ENR-CV increased the growth of wild-type organoids (p = 0.0114), but did not
signiﬁcantly change the growth of ApcMin/Min cysts (p = 0.8301). Graph shows values ± SD, Welch’s t tests were performed to calculate statistical
signiﬁcance. g Wild-type and ApcMin/Min organoids were treated with ENR-C, ENR-V, ENR-CV or ENR + 50% Wnt3A for 48 h and apoptosis determined
by measuring the number of cells with active caspase-3 using ﬂow cytometry. Data from four independent experiments normalised to the
percentage of apoptosis in ENR are shown. There was no signiﬁcant increase in apoptosis (p > 0.05 compared to ENR for all conditions). Staurosporine
was used as a positive control and increased apoptosis in wild-type organoids 6.2-fold (p < 0.0001). h Viability of HAB92 cells transfected with siApc or
untargeted control (siCtrl) shows siApc-transfected cells were signiﬁcantly less viable when treated with Chiron99021 compared to control media
(DSMO, p = 0.02), and compared to siCtrl-transfected cells treated with Chiron99021 (p = 0.009). Chiron and Valproic acid reduced the viability of
siApc-transfected cells compared to siCtrl-transfected cells (p = 0.03). The average of ﬁve independent experiments are shown ± SD. Statistics
compared each condition to control for siApc and siCtrl (directly above bars), and siApc to siCtrl for each condition (above lines) by t test
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Potentiating Wnt signalling with Chiron99021 in Apc
mutant organoids renders them more sensitive to
TSA-induced death
Reagents that inhibit Wnt signalling are currently
undergoing clinical trials as cancer therapies. However,
their therapeutic usefulness has been questioned because
of the potentially detrimental effects on wild-type cells2,25.
Wild-type organoids but not ApcMin/Min cysts died in the
absence of the Wnt agonist R-Spondin (Figure S5A) and
failed to grow in the presence of the Wnt inhibitor XAV-
939, conﬁrming the requirement of wild-type cells for
Wnt (Figure S5B). The diminished growth advantage of
Fig. 4 Increased Wnt signalling slows the growth of ApcMin/Min cysts and sensitises them to TSA-induced apoptosis. a Wildtype (top panels)
and ApcMin/Min (bottom panels) show organoid cultures after 72 h growth in different concentrations of Wnt3A-conditioned media. Scale bars = 500
µm. b Measuring organoid growth over 72 h reveals that Wnt3A signiﬁcantly slowed growth of ApcMin/Min cysts (p = 0.008, 0.006, 0.12 and 0.02 for
10%, 25%, 50% and 75% Wnt3A, respectively), while not affecting the growth of wild-type organoids (p > 0.05 in all conditions). The average of three
independent experiments show ± SD. Statistics compare growth in each concentration of Wnt3A-conditioned media to control conditions (ENR) by t
test. c Viability of HAB92 cells was signiﬁcantly increased by Wnt3A. The increase in viability was largest for siCtrl-transfected cell. At 50% Wnt3A,
viability increased signiﬁcantly more in siCtrl compared to siApc (p = 0.048). Average of ﬁve independent experiments show ± SD. Statistics compare
each condition to control for siApc and siCtrl (directly above bars), and siApc to siCtrl for each condition (above lines) by t test. d Schematic model for
how Wnt signalling affects growth. Wnt signalling increases growth until an optimal point is reached. Increasing Wnt beyond this optimal point
reduces cell growth (e.g. ApcMin/Min cysts grown in ENR-CV). e Relative increase in the proportion of apoptotic cells in wild-type and ApcMin/Min
organoids reveals that 24 h treatment with TSA increased apoptosis signiﬁcantly only in wild-type organoids (p < 0.05). However, co-treatment with
Chiron99021 protected wild-type organoids against this effect of TSA, but ApcMin/Min cysts died more readily in response to TSA treatment when
exposed to Chiron99021 (p < 0.05). Staurosporine increased apoptosis in wild-type organoids 6.74-fold (p < 0.01). Bar graph shows average values of
three independent experiments ± SD normalised to percentage apoptosis in ENR
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ApcMin/Min cysts that results from increasing Wnt sig-
nalling might facilitate the speciﬁc elimination of
ApcMin/Min cells. Indeed, we found that ApcMin/Min cysts
were more sensitive to the histone deacetylase inhibitor
TSA than wild-type organoids in the presence of
Chiron99021 (Fig. 4e), consistent with previous reports
that TSA and SAHA (another histone deacetylase inhi-
bitor) induce apoptosis in Wnt-activated colorectal cancer
cell lines26,27. We compared the number of apoptotic cells
in ApcMin/Min and wild-type organoids treated with TSA
and Chiron 99021. Strikingly, 24 h treatment of ApcMin/Min
cysts with TSA and Chiron99021 signiﬁcantly increased
the number of apoptotic cells, whereas wild-type orga-
noids were not signiﬁcantly affected (Fig. 4e). These data
suggest that stimulating Wnt in Apc mutant cells can
increase their susceptibility to TSA-induced death.
Discussion
Before exploiting cancer associated changes in Wnt
signalling, it is important to know how altering Wnt sig-
nalling affects wild-type and tumour cells. We show that
treatment with the combination of Chiron99021 and
Valproic acid reduces the proliferative advantage of Apc
mutant cells, and propose that this may be facilitated
through 'just-right' Wnt signalling. The novel concept
that 'just-right' Wnt signalling can be manipulated to
selectively eliminate Apc mutant cells is important to
consider when developing therapeutic interventions that
aim to eliminate Apc mutant cells in cancer.
In this context, it is noteworthy that an epidemiological
study by the Danish Cancer Registry found no association
between long-term use of the anti-depressant lithium, a
GSK3 inhibitor and Wnt agonist, and increased risk of
colorectal adenocarcinoma28. However, the region of the
colon where cancer occurred in these patients was dif-
ferent than in patients not treated with lithium. This is
consistent with the idea that the impact of increased Wnt
signals varies depending on the levels of endogenous Wnt
signalling present in different regions of the intestinal
tract. Similarly, Lithium did not signiﬁcantly increase
polyp load in ApcMin/+ mice29 and the GSK3 inhibitor
AZD7969 caused effects in dogs and rats that were
completely reversible30. Together these observations
suggest that increasing Wnt signalling may be a safe
means to increase the susceptibility of tumour cells to
targeted apoptosis.
Clinical exploitation of the 'just-right' Wnt signalling
hypothesis will require examination of whether organoids
derived from ApcMin/+ mice and human cancers respond
similarly. Human colorectal cancers may contain any of a
diverse range of Wnt-stimulating mutations31, and accu-
mulate a multitude of additional mutations during
development of the disease32, in contrast to the relatively
simple LOH-induced formation of ApcMin/Min cysts used
to establish the principle in this study. Organoids derived
from colorectal cancer patients have been shown to
recapitulate several properties of the original tumour33,
and could therefore allow testing of our hypothesis in a
more clinically relevant model.
Material and methods
Ethics statement
All experiments involving animals were performed in
accordance with UK Home ofﬁce approved guidelines and
were approved by the Home ofﬁce Licensing committee
(Project licenses PPL60/4172 and PPL70/8813).
Organoid culture
Organoids were generated from mouse small intestinal
crypts as described previously13. See Supplementary
Information for a full description. Additional reagents
(Chiron99012 [3 µM], Valproic acid [1 mM] and Y27632
[10 µM]; TSA, Wnt3A-conditioned media and XAV-939
[at indicated concentrations]) were added along with
standard media. To genotype organoids, DNA was iso-
lated by re-suspending one well of organoids in cold PBS,
collecting organoids in a pellet by centrifugation
(16,000× g, 30 s) and extracting them in microLYSIS-Plus
(Microzone) according to manufacturer’s instructions.
Genotypes of organoids was determined using standard
ApcMin/+ genotyping protocol (JAX lab). Organoid growth
was determined by measuring organoid area as previously
described34. Brieﬂy, the average percentage area occupied
by organoids was calculated from several non-overlapping
images of organoids grown for 72 h, and divided by the
average percentage area of freshly plated organoids (0 h)
from the same well.
Western blotting
Organoids or HAB92 cells were lysed in MEBC buffer
(50 mM Tris-HCl, pH 7.5, 100 mM NaCl, 5 mM EGTA, 5
mM EDTA, 0.5% NP-40 and 40 mM β-glycerol phos-
phate), lysates separated on 4–12% SDS-PAGE (Invitro-
gen), and transferred to Protran nitrocellulose membrane
(GE Healthcare). Immunoblotting was performed with
primary antibodies listed in Supplementary Information
and IRDye800/700-conjugated secondary antibodies
(Rockland, 1∶5000) were detected with LiCor Odyssey
Imager (Bioscience).
qPCR
RNA was isolated using a Nucelospin kit (Machery
Nagel) according to manufacturer’s instructions. A
volume of 1 µg RNA was reverse transcribed using qscript
cDNA Synthesis Kit (Quanta Biosciences), and 5 ng
cDNA was used as template for ampliﬁcation. An aliquot
of 0.1 µM forward and reverse primers (Supplementary
Information) were mixed with PerfeCTa SYBR Green
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Fastmix (Quanta Biosciences), and SYBR Green signal
detected using CFX connect real-time qPCR system (Bio-
Rad). Wnt target gene analysis (Figure S4) was carried out
using WNT signalling targets (SAB Target List) M96
plates (Bio-Rad) according to manufacturer’s instructions.
Cell culture
HEK293 and HAB92 cells were cultured in DMEM
(Gibco) supplemented with 10% FBS (GE Healthcare) and
1% penicillin-streptomycin (Life Technologies). For TOP/
FOP assays, HEK293 cells were plated at 5000 cells/well,
grown for 1 day and transfected with TOP-Renilla or
FOP-Renilla. After 1 day, fresh media containing
Chiron99021, Valproic acid or Wnt3A conditioned media
was added. Cells were incubated for 24 h, lysed and luci-
ferase activity measured using Luciferase Assay System kit
(Promega) according to manufacturer’s instructions.
Control cells were transfected with empty pBluescript
vector (negative control) or pCS2-β-catenin (positive
control). Viability assays were performed using HAB92
cells transfected with 10 nM of Apc-targeting or control
siRNAs (GE Healthcare) using INTERFERin (Polyplus)
according to manufacturer’s instructions. Cells were
grown for 48 h after transfection and passaged into 24-
well plates at 10,000 cells per well. Cells were grown for
24 h in different media conditions as described, and via-
bility measured using Cell TiterGLO (Promega) according
to manufacturer’s instructions. Luminescence was mea-
sured using LumatLB luminometer (Berthold
Technologies).
Immunoﬂuorescence
Immunoﬂuorescence was performed as previously
described for organoids18, cryo-sectioned intestinal tis-
sue35 and vibratome-sectioned intestinal tissue35 using
antibodies listed in Supplementary Information. Tissue
and organoids were imaged with a Zeiss LSM 710
microscope (Carl Zeiss AG, Oberkochen, Germany) using
×40 Zeiss objective lens and immersion oil with a
refractive index of 1.516. Z stacks were taken at 1 µm
steps.
Flow cytometry
Organoids were dissociated into single cells with Try-
pLE Express (37 °C, 5 min) and cells were collected by
centrifugation (2000rpm, 2 min). Cells were incubated in
PBS with LIVE/DEAD stain (ThermoFisher) (10min on
ice), washed in FACS buffer (1% FBS in PBS), ﬁxed in 0.5%
PFA (37 °C, 15 min), permeabilised in 70% ethanol (10
min on ice), washed in FACS buffer, stained with Active
Caspase-3 antibody (BD 560626) (30 min), washed and
then resuspended in FACS buffer. Cells were analysed
using LSRFortessa Cell Analyzer (BD Biosciences) and
data analysed in FlowJo.
Statistical analysis
All statistical analyses were performed using GraphPad
Prism 6.0a (GraphPad, La Jolla, CA) for Windows. Tests
performed are described in individual Figure legends,
along with p values and signiﬁcance (ns= not signiﬁcant,
*p< 0.05, **p< 0.01, ***p< 0.001, ****p< 0.0001).
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